MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ygyno.2023.04.014

Медицинская библиотека · Gynecologic oncology · 2023

Detection of endometrial cancer using tampon-based collection and methylated DNA markers.

Bakkum-Gamez Jamie N, Sherman Mark E, Slettedahl Seth W, Mahoney Douglas W, Lemens Maureen A, Laughlin-Tommaso Shannon K, Hopkins Matthew R, VanOosten Ann, Shridhar Viji, Staub Julie K, Cao Xiaoming, Foote Patrick H, Clarke Megan A, Burger Kelli N, Berger Calise K, O'Connell Maria C, Doering Karen A, Podratz Karl C, DeStephano Christopher C, Schoolmeester J Kenneth, Kerr Sarah E, Wentzensen Nicolas, Taylor William R, Kisiel John B

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Alterations in DNA methylation are early events in endometrial cancer (EC) development and may have utility in EC detection via tampon-collected vaginal fluid.

METHODS

For discovery, DNA from frozen EC, benign endometrium (BE), and benign cervicovaginal (BCV) tissues underwent reduced representation bisulfite sequencing (RRBS) to identify differentially methylated regions (DMRs). Candidate DMRs were selected based on receiver operating characteristic (ROC) discrimination, methylation level fold-change between cancers and controls, and absence of background CpG methylation. Methylated DNA marker (MDM) validation was performed using qMSP on DNA from independent EC and BE FFPE tissue sets. Women ≥45 years of age with abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB) or any age with biopsy-proven EC self-collected vaginal fluid using a tampon prior to clinically indicated endometrial sampling or hysterectomy. Vaginal fluid DNA was assayed by qMSP for EC-associated MDMs. Random forest modeling analysis was performed to generate predictive probability of underlying disease; results were 500-fold in-silico cross-validated.

RESULTS

Thirty-three candidate MDMs met performance criteria in tissue. For the tampon pilot, 100 EC cases were frequency matched by menopausal status and tampon collection date to 92 BE controls. A 28-MDM panel highly discriminated between EC and BE (96% (95%CI 89-99%) specificity; 76% (66-84%) sensitivity (AUC 0.88). In PBS/EDTA tampon buffer, the panel yielded 96% (95% CI 87-99%) specificity and 82% (70-91%) sensitivity (AUC 0.91).

CONCLUSION

Next generation methylome sequencing, stringent filtering criteria, and independent validation yielded excellent candidate MDMs for EC. EC-associated MDMs performed with promisingly high sensitivity and specificity in tampon-collected vaginal fluid; PBS-based tampon buffer with added EDTA improved sensitivity. Larger tampon-based EC MDM testing studies are warranted.

Для цитирования: Bakkum-Gamez Jamie N, Sherman Mark E, Slettedahl Seth W, Mahoney Douglas W, Lemens Maureen A, Laughlin-Tommaso Shannon K, Hopkins Matthew R, VanOosten Ann, Shridhar Viji, Staub Julie K, Cao Xiaoming, Foote Patrick H, Clarke Megan A, Burger Kelli N, Berger Calise K, O'Connell Maria C, Doering Karen A, Podratz Karl C, DeStephano Christopher C, Schoolmeester J Kenneth, Kerr Sarah E, Wentzensen Nicolas, Taylor William R, Kisiel John B. Detection of endometrial cancer using tampon-based collection and methylated DNA markers.. Gynecologic oncology. 2023. DOI: 10.1016/j.ygyno.2023.04.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.